Aug 03, 2017 4:05 pm EDT Capricor Therapeutics Second Quarter 2017 Update Webcast and Conference Call Scheduled for Thursday, August 10
Jul 27, 2017 6:00 am EDT Capricor Announces Results of FDA Meeting on Intravenous CAP-1002 for Duchenne Muscular Dystrophy
Jul 18, 2017 8:00 am EDT Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy
Jul 06, 2017 6:30 pm EDT Capricor Therapeutics Retains Full Rights to CAP-1002 as Janssen Biotech, Inc. Decides Not to Exercise Option
Jun 29, 2017 9:00 am EDT Six-Month Results from Capricor's HOPE-Duchenne Trial to be Presented at the 2017 PPMD Annual Connect Conference
Jun 01, 2017 8:00 am EDT Capricor Therapeutics to Present at the LD Micro Invitational Conference on June 6
May 31, 2017 7:00 am EDT Capricor Therapeutics Announces Upcoming Events in Duchenne Muscular Dystrophy Program
May 25, 2017 9:00 am EDT Capricor Therapeutics Announces Formation of Duchenne Muscular Dystrophy Advisory Board
May 15, 2017 4:15 pm EDT Capricor Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update